Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Gemcitabine in Transitional Cell Carcinoma of the Urothelium
NCT00191971Phase 2Completed
- Sponsor
- Eli Lilly and Company
- Start
- Jan 2004
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of gemcitabine in transitional cell carcinoma of the urothelium (TCC), sponsored by Eli Lilly and Company. Started Jan 2004; status: completed.
02
Drugs
gemcitabine
03
Conditions
transitional cell carcinoma of the urothelium (TCC)
Beyond the preview
Go deeper on NCT00191971.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00191971.